VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $717,647,365 | +2.2% | 14,077,037 | +0.1% | 0.06% | +5.1% |
| Q2 2023 | $701,968,411 | -20.7% | 14,056,236 | -40.5% | 0.06% | +47.5% |
| Q1 2023 | $885,170,052 | +81.5% | 23,617,130 | +132.2% | 0.04% | -16.7% |
| Q4 2022 | $487,617,048 | +128.4% | 10,169,282 | +14.3% | 0.05% | +118.2% |
| Q3 2022 | $213,533,000 | +15.3% | 8,897,197 | +4.5% | 0.02% | +22.2% |
| Q2 2022 | $185,253,000 | -8.4% | 8,513,406 | +1.6% | 0.02% | +12.5% |
| Q1 2022 | $202,304,000 | +8.0% | 8,376,942 | +6.4% | 0.02% | +14.3% |
| Q4 2021 | $187,331,000 | -5.7% | 7,874,350 | +0.6% | 0.01% | -12.5% |
| Q3 2021 | $198,605,000 | +14.5% | 7,828,385 | +1.6% | 0.02% | +14.3% |
| Q2 2021 | $173,480,000 | +14.1% | 7,706,809 | +0.1% | 0.01% | +7.7% |
| Q1 2021 | $152,059,000 | -25.1% | 7,699,143 | +0.7% | 0.01% | -27.8% |
| Q4 2020 | $203,058,000 | -35.5% | 7,642,405 | +19.9% | 0.02% | -43.8% |
| Q3 2020 | $314,836,000 | +111.6% | 6,375,763 | +35.5% | 0.03% | +100.0% |
| Q2 2020 | $148,780,000 | – | 4,706,759 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |